Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
作者： Hari Deshpande , Sanziana Roman , Jaykumar Thumar , Julie Ann Sosa
DOI: 10.4137/CMO.S6197
关键词:
摘要: … Further studies on human umbilical vein endothelial cells (HUVEC) have found vandetanib … (IC50 60 nM) with higher doses necessary for EGFR stimulated HUVEC proliferation (IC50 …
sagepub.com
sci-hub.se 参考文章(34)
R. Kurzrock, E. E. Cohen, S. I. Sherman, D. G. Pfister, R. B. Cohen, D. Ball, D. S. Hong, C. S. Ng, R. Salgia, M. J. Ratain, Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Journal of Clinical Oncology. ,vol. 28, pp. 5502- 5502 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.5502
Marinella Messina, Bruce G Robinson, Technology Insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma Nature Clinical Practice Endocrinology & Metabolism. ,vol. 3, pp. 290- 301 ,(2007) , 10.1038/NCPENDMET0420
Lisa K. Gilliam, Aimee D. Kohn, Tasneem Lalani, Paul E. Swanson, Vasyl Vasko, Aneeta Patel, Robert B. Livingston, Cheryl A. Pickett, Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid. ,vol. 16, pp. 801- 810 ,(2006) , 10.1089/THY.2006.16.801
ALTON L. STEINER, A DAVID GOODMAN, SAMUEL R. POWERS, Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine. ,vol. 47, pp. 371- 409 ,(1968) , 10.1097/00005792-196809000-00001
Sanziana Roman, Rong Lin, Julie Ann Sosa, Prognosis of medullary thyroid carcinoma Cancer. ,vol. 107, pp. 2134- 2142 ,(2006) , 10.1002/CNCR.22244
Napoleone Ferrara, Hans-Peter Gerber, Jennifer LeCouter, None, The biology of VEGF and its receptors. Nature Medicine. ,vol. 9, pp. 669- 676 ,(2003) , 10.1038/NM0603-669
Hari A Deshpande, Scott N Gettinger, Julie Ann Sosa, Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Current Opinion in Oncology. ,vol. 20, pp. 19- 24 ,(2008) , 10.1097/CCO.0B013E3282F28373
R. Kurzrock, S. Sherman, D. Hong, C. Ng, J. Frye, L. Janisch, M.J. Ratain, R. Salgia, 379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC) Ejc Supplements. ,vol. 6, pp. 119- ,(2008) , 10.1016/S1359-6349(08)72313-9
Masahide Takahashi, Jerome Ritz, Geoffrey M. Cooper, Activation of a novel human transforming gene, ret, by DNA rearrangement Cell. ,vol. 42, pp. 581- 588 ,(1985) , 10.1016/0092-8674(85)90115-1
Clarissa Capp, Simone Magagnin Wajner, Débora Rodrigues Siqueira, Beatriz Assis Brasil, Luise Meurer, Ana Luiza Maia, Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma Thyroid. ,vol. 20, pp. 863- 871 ,(2010) , 10.1089/THY.2009.0417